Publications

Publication of research results is a pivotal requirement for a comprehensive improvement of treatment concepts. iOMEDICO supports the international guidelines for transparency and reporting of medical research results.

We regularly present our data at national and international conferences. Our publications are published in scientifically renowned, international journals. Authors are principal investigators, investigators with a high number of participating patients, and scientists of iOMEDICO.

TITEL
STUDIE
JAHR
Clinical reserach platform into molecular testing, treatment and outcome of NSCLC (CRISP)

F. Griesinger, 2020.

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: DKK / Journal: Oncology Research and Treatment
CRISP
2020
Advanced renal cell carcinoma: first results from the prospective research platform CARAT for patients with mRCC in Germany.

Goebell, P.J., Grüllich, C., Reichert, D., Bögemann, M., Dörfel, S., von der Heyde, E., Binninger, A., Jänicke, M., Marschner, N., Staehler, M., Grünwald, V., 2020.

Oncol Res Treat 43 (suppl 1)(391), 76.

Indikation: Urogenital Tumors, Urogenitale Tumore / Veranstaltung: DKK / Journal: Oncology Research and Treatment
CARAT
2020
Molekulare Testung von Patienten mit EGFR-Mutations-positivem lokal fortgeschrittenem oder metastasiertem nicht-kleinzelligen Lungenkarzinom im Behandlungsalltag – Aktualisierte Zwischenergebnisse der Registerstudie PANORAMA.
Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: DKK / Journal: Oncology Research and Treatment
PANORAMA
2020
Nab-paclitaxel plus carboplatin as first-line therapy for patients with advanced NSCLC in the real-world setting: Safety results of the non-interventional NEPTUN study.

Dechow, T., Riera-Knorrenschild, J., Hackanson, B., Fischer von Weikersthal, L., Chiabudini, M., Timm, B., Zerbes, R.M., Potthoff, K., 2020.

Oncol Res Treat 43 (suppl 1)(276), 112.

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: DKK / Journal: Oncology Research and Treatment
NEPTUN
2020
Real-world testing patterns for BRAF-mutations and treatment of patients with BRAF-mutated metastatic colorectal cancer: Results from the German Tumor Registry Colorectal Cancer (TKK Registry)

Zahn, M.-O., Dörfel, S, Schulz, H., Wolf, T., Vehling-Kaiser, U., Tech, S., Jänicke, M., Wetzel, N., Marschner N., 2020.

Oncol Res Treat 43(suppl 1)(426), 52.

Indikation: Colorectal Cancer, Kolorektalkarzinom / Veranstaltung: DKK / Journal: Oncology Research and Treatment
TKK
2020
The Prospective Intersectoral National Cohort Study MYRIAM To Study Characteristics, Treatment And Outcome Of Patients With Multiple Myeloma In Germany.

Knauf, W., Engelhardt, M., Losem, C., Lipke, J., Kasper, C., Houet, L., Medinger, T., Jänicke, M., Marschner, N., Dechow, T., Einsele, H., 2020.

Oncol Res Treat, DKK 43 (suppl 1)(392), 130.

Indikation: Haemoblastoma, Hämoblastosen / Veranstaltung: DKK / Journal: Oncology Research and Treatment
MYRIAM
2020
Routine care of advanced breast cancer: the prospective, national research platform OPAL for patients with advanced breast cancer in Germany.

Decker T., Harbeck N., Thill M., Zahn M.-O., Nusch A., Lorenz A., Söling U., Chiabudini M., Kruggel L., Jänicke M., Marschner N., Stickeler E., Wöckel A., Welt A., 2020.

Oncol Res Treat 43(suppl 1)(254), 12.

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: DKK / Journal: Oncology Research and Treatment
OPAL
2020
Reduction of severity of chemotherapy-induced peripheral neuropathy by OnLife®14.02.2020 Final results of the breast cancer cohort of the STEFANO trial.

Zaiss, M., Uhlig, J., Zahn, M.-O., Decker, T., Lehmann, H., Harde, J., Hogrefe, C., Vannier, C., Marschner, N., 2020.

Oncol Res Treat 43 (suppl 1)(405), 185.

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: DKK / Journal: Oncology Research and Treatment
STEFANO
2020
Palbociclib plus fulvestrant as second- or later-line therapy for patients with locally advanced, inoperable or metastatic HR+/HER2- breast cancer in Germany: Interim results of the INGE-B phase 2 study.

Lüftner, D., Welslau, M., Liersch, R., Deryal, M., Brucker, C., Rauh, J., Welt, A., Zaiss, M., Houet, L., Vannier, C., Potthoff, K., Marschner, N., 2020.

Oncol Res Treat 43 (suppl 1)(272), 14.

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: DKK / Journal: Oncology Research and Treatment
INGE-B
2020
Palbociclib plus fulvestrant as first-line therapy for patients with locally advanced, inoperable or metastatic HR+/HER2- breast cancer in Germany: Interim results of the INGE-B phase 2 study.

Welt, A., Welslau, M., Lüftner, D., Deryal, M., Liersch, R., Sahlmann, J., Houet, L., Potthoff, K., Marschner, N., 2020.

Oncol Res Treat 43 (suppl 1)(270), 13–14.

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: DKK / Journal: Oncology Research and Treatment
INGE-B
2020